CA2286452A1 - Composes de pyrimido-isoquinoline a action anticonvulsive - Google Patents

Composes de pyrimido-isoquinoline a action anticonvulsive Download PDF

Info

Publication number
CA2286452A1
CA2286452A1 CA002286452A CA2286452A CA2286452A1 CA 2286452 A1 CA2286452 A1 CA 2286452A1 CA 002286452 A CA002286452 A CA 002286452A CA 2286452 A CA2286452 A CA 2286452A CA 2286452 A1 CA2286452 A1 CA 2286452A1
Authority
CA
Canada
Prior art keywords
pyrimido
dihydro
isoquinolin
dimethoxy
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002286452A
Other languages
English (en)
Inventor
Barry Sidney Orlek
Peter Ainsworth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2286452A1 publication Critical patent/CA2286452A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur une nouvelle méthode de traitement consistant à administrer au patient le nécessitant une dose efficace ou prophylactique d'un composé de formule (I) ou de ses sels ou solvates pharmacocompatibles. Dans ladite formule: R?1¿ est H, ou jusqu'à trois substituants choisis indépendamment parmi halogène, C¿1-6? alkyle, C¿1-6? alkoxy, C¿1-6? alkylcarbonyle et hydroxy C¿1-6? alkyle, ou bien deux groupes R?1¿ forment un méthylènedioxy; R?2¿ est H ou C¿1-6? alkyle, et R est R?3¿ ou R?3¿CO, où R?3¿ est C¿3-7? cycloalkyle, phényle ou phényle C¿1-6? alkyle dans lequel les fragments cycliques sont facultativement substitués par jusqu'à trois substituants choisis indépendamment parmi halogène, C¿1-6? alkyle, C¿1-6? alkoxy, C¿1-6? alkylcarbonyle, hydroxy C¿1-6? alkyle et phénylcarbonyloxy C¿1-6? alkyle. Ledit composé assure le traitement ou la prophylaxie de: l'anxiété, de la manie, de la dépression, des troubles liés à la panique ou au comportement agressif, des troubles associés à l'hémorragie méningée, au choc neural, des troubles liés à la désintoxication (cocaïne, nicotine, alcool et benzodiapézine) et pouvant être traités ou prévenus par des agents anticonvulsifs (dont l'épilepsie et l'épilepsie post traumatique), de la maladie de Parkinson, des psychoses, de la migraine, de l'ischémie cérébrale, de la maladie d'Alzheimer et autres affections dégénératives (dont la chorée de Huntingdon), de la schizophrénie, des névroses obsessionnelles, des troubles neurologiques associés au SIDA, des troubles du sommeil (dont les troubles du rythme circadien, l'insomnie et la narcolepsie), des tics (dont le syndrome de Gilles de la Tourette), des lésions traumatiques du cerveau, des acouphènes, des névralgies (y compris les névralgies faciales), des douleurs névropathiques, des douleurs dentaires, des douleurs cancéreuses, de l'activité anormale des neurones conduisant à la neurodysthésie dans des maladies telles que le diabète, des maladies de l'AM et des neurones moteurs, de l'ataxie, de la raideur musculaire (spasticité), du dysfonctionnement de l'articulation temporo-mandibulaire, et de la sclérose latérale amyotrophique.
CA002286452A 1997-04-10 1998-04-03 Composes de pyrimido-isoquinoline a action anticonvulsive Abandoned CA2286452A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9707251.6A GB9707251D0 (en) 1997-04-10 1997-04-10 Novel method and compounds
GB9707251.6 1997-04-10
PCT/EP1998/002139 WO1998045293A1 (fr) 1997-04-10 1998-04-03 Composes de pyrimido-isoquinoline a action anticonvulsive

Publications (1)

Publication Number Publication Date
CA2286452A1 true CA2286452A1 (fr) 1998-10-15

Family

ID=10810566

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002286452A Abandoned CA2286452A1 (fr) 1997-04-10 1998-04-03 Composes de pyrimido-isoquinoline a action anticonvulsive

Country Status (5)

Country Link
EP (1) EP0973773A1 (fr)
JP (1) JP2001519798A (fr)
CA (1) CA2286452A1 (fr)
GB (1) GB9707251D0 (fr)
WO (1) WO1998045293A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007092A2 (fr) * 2003-07-08 2005-01-27 Smithkline Beecham Corporation Nouveaux composes chimiques
EP2619203A4 (fr) * 2010-09-20 2014-04-16 Glaxo Group Ltd Composés tricycliques, leurs procédés de préparation et leurs utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1237429A (fr) * 1983-05-05 1988-05-31 Frank Kienzle Derives de pyrimidone
FI895463A0 (fi) * 1988-11-19 1989-11-16 Hoechst Ag Farmaceutiska kompositioner, som innehaoller labdanditerpenoidderivat och pyrimido (6,1-a) isokinolin -4-onderivat, samt anvaendning daerav.
US5114944A (en) * 1991-04-12 1992-05-19 A. H. Robins Company Incorporated 2-phenylpyrazolo[1,5-a]pyrimidine-3-acetic acid derivatives exhibiting therapeutic effects

Also Published As

Publication number Publication date
JP2001519798A (ja) 2001-10-23
EP0973773A1 (fr) 2000-01-26
WO1998045293A1 (fr) 1998-10-15
GB9707251D0 (en) 1997-05-28

Similar Documents

Publication Publication Date Title
CA2053640C (fr) Derives de la quinoline
JP2001507349A (ja) 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
NO340744B1 (no) Pyrimidinforbindelser som serotoninreseptormodulatorer
IE913175A1 (en) Aryl-fused and hetaryl-fused-2, 4-diazepine and 2,¹4-diazocine antiarrhythmic agents
JP3044055B2 (ja) １，２―エタンジオール誘導体およびその塩
RU2284997C2 (ru) Производные пиримидина и фармацевтическая композиция
NZ250580A (en) 3-(hetero)aryloxymorphinan derivatives and their use in the manufacture of medicaments
CA2288171A1 (fr) Derives de pyridazine et de phtalazine, leur procede de preparation et leur utilisation comme anti-convulsifs
SK3872000A3 (en) 3-SUBSTITUTED TETRAHYDROPYRIDOPYRIMIDINONE DERIVATIVES, METHODì (54) FOR PRODUCING THE SAME, AND THEIR USE
AU744451B2 (en) Substituted isoquinoline derivatives and their use as anticonvulsants
US5373015A (en) Fused pyridine derivatives useful as angiotensin II antagonists
EP0354781B1 (fr) Composés de benzodiazépine et leur utilisation comme médicaments
CA2286452A1 (fr) Composes de pyrimido-isoquinoline a action anticonvulsive
WO1999038864A1 (fr) Derives d'oxazol utilises comme agonistes du recepteur 1a de la serotonine
WO1999015526A2 (fr) Nouveaux composes
US5389684A (en) Naphthalene carboxamides
EP1200409B1 (fr) Derives d' isoquinoleine substituee et leur utilisation comme anticonvulsants
US6410555B1 (en) Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity
US6057340A (en) Oxazole derivatives as serotonin-1A receptor agonists
WO1999052857A1 (fr) Nouveaux composes
WO2000008022A1 (fr) Derives uree
CZ20002221A3 (cs) Substituované deriváty isochinolinu a jejich použití jako antikonvulziva
MXPA00003136A (en) 2-substituted 1,2-benzisothiazole derivatives and their use as serotonin antagonists (5-ht1a, 5-ht1b and 5-ht1d)
MXPA00002601A (en) 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use

Legal Events

Date Code Title Description
FZDE Dead